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According to some recent studies, Cameroon is one of the sub-Saharan African
countries most affected by hepatitis C, with low access to the standard therapy based
on the combination of pegylated interferon and ribavirin. A first ethnobotanical survey,
conducted in the Western region of Cameroon, reported the use of several medicinal
plants in traditional medicine for the healing of liver-related disorders. Crude organic
extracts of five plants surveyed were prepared and their effect against hepatitis C virus
(HCV) infection investigated. The HCV JFH1 strain cell culture system HCVcc was used.
The antiviral activity was quantified by immunofluorescent labeling of HCV E1 envelope
protein at 30 h post-infection in the presence of the plant extracts. Active compounds
were then tested in time course infection experiments. Dose-response and cellular
toxicity assays were also determined. Three extracts, methanol extracts from roots
of Trichilia dregeana, stems of Detarium microcarpum and leaves of Phragmanthera
capitata, showed anti-HCV activity, with half-maximal inhibitory concentration of 16.16,
1.42, and 13.17 μg/mL, respectively. Huh-7 cells were incubated with the extracts for 72
h and it appears that T. dregeana extract is not toxic up to 200 μg/mL, D. microcarpum
up to 100 μg/mL and P. capitata up to 800 μg/mL. All the three extracts showed a
strong inhibition of HCV entry and no effect on replication or secretion. Taken together,
these results showed that extracts from Cameroonian medicinal plants are promising
sources of anti-HCV agents.
Keywords: hepatitis C, plant extract, entry inhibitor, traditional medicine, natural compounds
Introduction
Hepatitis C virus (HCV) infection is one of the major causes of chronic hepatitis, and related
complications such as steatosis, ﬁbrosis, cirrhosis, and hepatocellular malignancies (Sangiovanni
et al., 2006). According to WHO, approximately 130–170 millions people are chronically infected
by HCV globally and over a million new cases occur each year. In Africa, a recent study reported
that more than 28 millions people are chronically infected by the virus (Lavanchy, 2011). However,
the prevalence data are still incomplete and vary considerably from one population studied to
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another. In Cameroon, the prevalence of hepatitis C is high and
was estimated to about 13% of the whole population (Nerrienet
et al., 2005), with a great predominance of genotypes 1, 2, and
4 (Ndjomou et al., 2002). Phylogenetic analysis performed with
viral isolates coming from Cameroonian patients infected by
genotype 1 strains, revealed a high diversity in this genotype.
Seven genotype 1 subtypes (1a–1c, 1e, 1g, 1h, 1l) and two unclas-
siﬁed lineages were recently identiﬁed and characterized (Li et al.,
2013).
To date, there is no vaccine against hepatitis C and the great
diversity of viral isolates makes its development diﬃcult. Over the
last decade, the standard therapy against hepatitis C was based
on the combination of pegylated-interferon α-2a or 2b (Peg-
IFNα) with ribavirin (RBV), a guanosine analog. This treatment
allowed reaching a sustained virological response (SVR) of 76–
84% in genotype 2-infected patients and only 40–50% in genotype
1-infected patients (Mauss et al., 2013). Nevertheless, a poor
therapeutic response (56%) was observed with this combina-
tion in genotype 2-HCV infected Cameroonians (Njoya et al.,
2013). In 2011, two NS3/4A protease inhibitors (Boceprevir
and Telaprevir) were approved by the American Agency for
Food and Drug Administration (FDA) and are now used in
association with the standard bitherapy to improve the viral
clearance rates in genotype 1 infected patients. Cure rates of
approximately 70% were achieved with this triple combina-
tion in these patients. Recently, in 2013, two more eﬀective
compounds were approved to reinforce the therapeutic arsenal:
Simeprevir, a protease inhibitor and Sofosbuvir a polymerase
inhibitor. In October 2014, FDA approved a new drug for hepati-
tis C treatment: Harvoni which is a combination of Sofosbuvir
and Ledipasvir (Keating, 2015). This drug is used for a 12-week
course treatment and has the advantage that no IFN or RBV
is needed and higher SVR rates are achieved. However, if these
molecules are eﬀective, they are not really accessible for most-
infected patients especially in low-income countries, and less than
10% of identiﬁed patients are cured with the standard bitherapy.
Moreover the side eﬀects of Peg-IFNα and these inhibitors as well
as emergence of resistant HCV variants remain a problem. It is
currently thought that combinations of multiple direct antiviral
agents (DAAs) without Peg-IFNα may lead to higher SVR rates.
Eﬀorts are then needed to identify such ingredients in medicinal
plants.
A ﬁrst ethnobotanical survey, conducted in the Western
region of Cameroon, reported the use of 53 medicinal plants
in the Bamun folk medicine for the management of jaundice
and other hepatic disorders. Antioxidant properties of these
plants were demonstrated in vitro on microsomal lipid peroxi-
dation and protein oxidation (Njayou et al., 2008). Recently,
we found that the crude extract and fractions of Entada
africana, one of these plants, possessed an anti-HCV activity
in genotype 1b replicons systems (Galani Tietcheu et al.,
2014). However with most of these plants, no eﬀect on HCV
infection has yet been reported. Recent studies highlighted
the eﬃcacy of molecules from plant origin as anti-HCV
agents (Calland et al., 2012b). Among them, epigallocatechin
gallate (EGCG; Ciesek et al., 2011; Calland et al., 2012a;
Chen et al., 2012), ladanein (Haid et al., 2012) and cucurmin
(Anggakusuma et al., 2013) are the most promising inhibitors.
Due to their low cost of production, extracts, or molecules
isolated from plants used in traditional medicine might be
useful in the therapeutic arsenal against hepatitis C in low
income countries. In this study, we tested seven diﬀerent extracts
from ﬁve plants and report the anti-HCV activity of three
Cameroonian plant extracts by the use of HCV cell culture
system (HCVcc), representing the complete infectious cycle of the
virus.
Material and Methods
Chemicals
Dulbecco’s modiﬁed Eagle’s medium (DMEM), glutamax-I,
goat, and fetal calf sera were purchased from Invitrogen
(Carlsbad, CA, USA). 4′,6-Diamidino-2-phenylindole (DAPI)
was from Molecular Probes (Life technologies). EGCG was from
Calbiochem (Merck Chemicals, Darmstadt, Germany). Stocks
were resuspended in dimethyl sulfoxide (DMSO) at 0.5 M for
EGCG and 250 mg/mL for plant extracts. Boceprevir was kindly
provided by Philippe Halfon (Hôpital Européen, Laboratoire
Alphabio, Marseille, France).
Antibodies, Cells, and Culture Conditions
Mouse anti-E1monoclonal antibody (MAb)A4 (Dubuisson et al.,
1994) was produced in vitro. Cy3-conjugated goat anti-mouse
IgG was from Jackson Immunoresearch (West Grove, PA, USA).
Huh-7 hepatoma cells (Nakabayashi et al., 1982) were grown in
DMEM supplemented with glutamax-I and 10% fetal calf serum,
in an incubator at 37◦C with 5% CO2. The cells were split three
times a week.
HCV Grown in Huh-7 Cell Culture (HCVcc)
We used a modiﬁed JFH1 (Japanese Fulminant Hepatitis-1) virus
containing titer-enhancing mutations (Delgrange et al., 2007)
and in which the A4 epitope of HCV glycoprotein E1 of strain
H77 was reconstituted (Goueslain et al., 2010). The viral stock
was produced in Huh-7 cells. The titer of the stock was 5.105 focus
forming unit (ﬀu)/mL.
Selection, Collection, and Extraction of
Medicinal Plants
Several medicinal plants used in traditional medicine for the
healing of liver-related disorders were identiﬁed in the Western
region of Cameroon. Five of these plants, Discoglypremna
caloneura (Euphorbiaceae), T. dregeana (Meliaceae), Detarium
microcarpum (Caesalpinaceae), P. capitata (Loranthaceae), and
Tapinanthus bangwensis (Loranthaceae) were investigated for
their anti-HCV activity (Table 1). These plant materials were
collected near Yaounde Central region of Cameroon. After collec-
tion, all materials were veriﬁed by Mr. Nana, plant taxonomist at
the National Herbarium of Cameroon in Yaounde.
The stem and root of D. caloneura (Euphorbiaceae) were
collected in May 2012 in Ezezang near Yaounde town central
region of Cameroon. A voucher specimen was deposited at the
National Herbarium of Cameroon under the N◦ 4207/ SFR/
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TABLE 1 | List of the plants used for the preparation of crude extracts tested for their anti-hepatitis C virus (anti-HCV) activity.
Botanical name Family Voucher number Parts Type of extract No
Discoglypremna caloneura Euphorbiaceae 4207/SFR/Cam Stem bark Crude extract F1
Roots Crude extract F2
Trichilia dregeana Meliaceae 2126/SFR/Cam Roots Crude extract F3
Detarium microcarpum Caesalpiniaceae 49834/SFR/Cam Stem bark Crude extract F4
Phragmantera capitata Loranthaceae 5068/SFR/Cam Leaves Crude extract F5
Tapinanthus bangwensis Loranthaceae 18628/SFR/Cam Fruits Crude extract F6
Leaves Crude extract F7
CAM. Air-dried and powdered stem and root of D. caloneura
(2,2 and 1,5 kg, respectively) were exhaustively extracted twice
at room temperature for 72 h using 98% methanol (static
maceration). Each suspension was ﬁltered using Whatman paper
2 and the resulting ﬁltrate was concentrated under vacuum
using a rotary evaporator under reduced pressure to give
120 g of brown residue and 70 g of oily material, respec-
tively.
The root of T. dregeana (Meliaceae) was collected in July
2011, in Eloumden Mountain near Yaounde town central
region of Cameroon. A voucher specimen was deposited at the
National Herbarium of Cameroon under the N◦ 2126/SFR/CAM.
Using the same procedure of extraction as above on air-dried
and powdered root (3.5 kg), we obtained 200 g of black
residue.
The stem bark of D. microcarpum (Caesalpiniaceae) was
collected in February 2013 in Puma, a locality of the Littoral
region of Cameroon. A voucher specimen was deposited
at the National Herbarium of Cameroon under the N◦
49834/SFR/CAM. Using the same procedure of extraction as
above on air-dried and powdered root (4 kg), we obtained 430 g
of red residue.
The leaves of P. capitata (Loranthaceae) were collected in
November 2012 on the Campus of the University of Yaounde I.
A voucher specimen was deposited at the National Herbarium
of Cameroon under the N◦ 5068/SFR/CAM. Using the same
procedure of extraction as above on air-dried and powdered
leaves (2 kg), we obtained 150 g of green residue.
The fruits and leaves of T. bangwensis (Loranthaceae) were
collected in November 2012 on the Campus of the University of
Yaounde I. A voucher specimen was deposited at the National
Herbarium of Cameroon under the N◦ 18628/SFR/CAM.
Using the same procedure of extraction as above on air-
dried and powdered fruits (1.6 kg) and leaves (1.8 kg), we
obtained 500 g of brown residue and 120 g of green residue,
respectively.
All the plant extracts were stored at 4◦C until their use for
biological tests and further phytochemical investigations. The
extracts for bioassay were dried in vacuo before being used.
A total of seven extracts, F1 to F7 were obtained (Table 1).
HCVcc Inhibition Assay
General Procedure
During the inhibition assay, the cells were maintained in an
incubator at 37◦C with 5% CO2. The day before infection,
Huh-7 cells were plated in 96-well plates at a concentration of
6.000 cells/well. Huh-7 cells were infected for 2 h with HCVcc
at a multiplicity of infection (MOI) of 0.5. The inoculum was
removed and cells were overlaid with fresh medium. After 28 h,
infected cells were ﬁxed with ice-cold methanol. DMSO (0.01%)
was used as a control because this solvent was used to prepare
stocks of plant extract.
Identification of Active Plant Extracts
For the ﬁrst screening of the plant extracts, F1, F2, F4, F6, or F7
extract at 25 μg/mL, or F3 or F5 extract at 125 μg/mL, was added
to the culture medium during the 2 h inoculation period and the
28 h post-inoculation period.
Effect on Virus Entry or Replication Step
To test the eﬀect of the compounds on entry or replica-
tion, the same amount of each extract was added either
during the 2 h inoculation period, the viral entry step,
or the 28 h post-inoculation period, the viral replication
step. In parallel, the compounds were added to the culture
medium during both inoculation and replication steps, contin-
uously. EGCG, an inhibitor of the entry step (Calland et al.,
2012a), was added as a control at 50 μM during the 2 h-
inoculation step. Boceprevir, a viral NS3/4A protease inhibitor
(Sarrazin et al., 2012), inhibiting the replication step, was
added as a control at 1 μM during the 28 h-post-inoculation
step.
Effect on Virus Assembly/Secretion Step
To test the eﬀect of the compounds on the assembly/secretion
step, Huh-7 cells were inoculated for 2 h with HCVcc, the
inoculum was removed and replaced with DMEM containing
25 μg/mL of F1, F2, F6, or F7 extract for 46 h. This period of
time allows the secretion of viral particles in the medium. The
medium containing the virus was collected and used to inoculate
Huh-7 cells for 2 h. The inoculum was removed and replaced by
culture medium without plant extract for 28 h. Cells were ﬁxed
with ice-cold methanol.
Immunofluorescent Detection Assay
Cells were then processed for immunoﬂuorescent detection
of E1 envelope glycoprotein with Cy3-labeled antibody as
previously described (Rouille et al., 2006). Nuclei were stained
with 1 μg/mL DAPI. Confocal images were recorded on an
automated confocal microscope IN Cell Analyzer 6000 (GE
Healthcare Life Sciences) using a 20X objective with exposure
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parameters 405/450 nm and 561/610 nm. Six ﬁelds per well
were recorded. Each image was then processed using the
Columbus image analysis software (Perkin Elmer). Nuclei were
ﬁrst segmented and cytoplasm region extrapolated based on
the DAPI staining. Then a cell was considered “infected” for a
high ratio of the intensity of the Cy3 staining in the cytoplasm
region (relative to that of the nucleus) and Cy3 intensity above
a ﬁxed threshold. Quantity of cells per well and MOI were
calculated to obtain no more than 40% of infected cells 30 h
post infection, allowing the automated quantiﬁcation. Data
were then normalized to DMSO control set-up at 100% of
infection.
Determination of the Half-Maximal Inhibitory
Concentrations (IC50)
Huh-7 cells were inoculated for 2 h with HCVcc in the presence
of 0.1, 1.25, 2.5, 5, 10, 25, 50, 100, 200, 400, or 800 μg/mL of
F3 or F5 extract and, 0.01, 0.0625, 0,125, 0.25, 0.5, 1, 2.5, 5, 10,
25, 50, 100 μg/mL of F4 extract. The inoculum was removed and
replaced with culture mediumwithout extract for 28 h. Cells were
ﬁxed in iced-cold methanol and processed for immunoﬂuores-
cent detection assay. IC50 values were calculated via non-linear
regression analysis using a variable-sloe log dose-versus-response
curve with a least square (ordinary) using Prism 5 software
(GraphPad Software Inc).
Viability Assay
The day before incubation with the plant extracts, Huh-
7 cells were plated in 96-well plates at a density of
6.000 cells/well and placed in the incubator at 37◦C
with 5% CO2. Cells were incubated in 100 μL of culture
medium containing diﬀerent concentrations of the plant
extracts (three wells per condition) for either 24, 48, or
72 h in the incubator at 37◦C with 5% CO2. An MTS
[3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-
(4-sulfophenyl)-2H-tetrazolium]-based viability assay (CellTiter
96 AQueous non-radioactive cell proliferation assay, Promega)
was conducted as recommended by the manufacturer. Brieﬂy, at
the diﬀerent time points, the cell culture medium was replaced
by 100 μl of DMEM and 20 μl of MTS/phenazine methosulfate
(PMS) solution, which is transformed in formazan in viable cells,
and the plate further incubated at 37◦C for 45 min to 2 h. The
amount of formazan was quantiﬁed by measuring absorbance at
490 nm, recorded using an ELISA plate reader (ELX 808 Bio-Tek
Instruments Inc).
Statistical Analysis
The results were presented as means ± SEM of triplicate experi-
ments. The data were analyzed using Prism statistical software
(Graph Pad Inc.) using Mann–Whitney non-parametric test with
a conﬁdence interval of 95%. Comparisons were made between
each treated group and untreated group (DMSO control). We
report two-tailed p-values. Diﬀerences between treated and
control groups were considered signiﬁcant for any p-value< 0.05.
P-values were indicated whenever signiﬁcant diﬀerences were
observed.
Results
Identification of Cameroonian Plant Extracts
with Anti-HCV Activity
A ﬁrst ethnobotanical survey, conducted in the Western
region of Cameroon, reported the use of several medicinal
plants in traditional medicine for the healing of liver-related
disorders. Five of these plants, D. caloneura, T. dregeana,
D. microcarpum, P. capitata, and T. bangwensis were investi-
gated for their anti-HCV activity. Seven crude plant extracts,
F1 to F7 were prepared from diﬀerent parts of these plants
(Table 1). The HCVcc system used enables analyzing antivi-
ral eﬀect of the compounds during a complete viral life cycle.
Plant extracts were solubilized in DMSO at a ﬁnal concen-
tration of 250 mg/mL and used in anti-HCV experiments
at 250 μg/mL in a ﬁrst set of experiments. This concen-
tration appeared to be toxic for Huh-7 cells for a vast
majority of extracts because the total cell number at the
end of the experiment was decreased by 99.3, 89.4, 28.3,
61.4, 11.3, 99.3, 98.3%, for F1 to F7 extracts, respectively,
compared to DMSO control (data not shown). The concen-
tration was then lowered to 25 μg/mL except for F3 and
F5 that were tested at 125 μg/mL because they were less
toxic.
Plant extracts were added during both the 2 h inoculation
step and the 28 h post-inoculation step. A 30 h infectious
cycle allows us to avoid detecting re-infection events by newly
synthesized particles. Infected cells were ﬁxed and submit-
ted to immunoﬂuorescence labeling with an anti-E1 envelope
protein antibody (Figure 1B). The total number of cells at the
end of the experiment was determined by staining of nuclei
with DAPI (Figure 1A). The results presented in Figure 1A
show that the compounds were not toxic for the cells at the
concentration tested because similar numbers of cells were
present in the control and the diﬀerent plant extract samples.
A signiﬁcant decrease in the number of infected cells was
observed for F3, F4 and F5 extracts that showed more than
95% of inhibition in HCV infection at the concentration tested
(Figure 1B), demonstrating a strong anti-HCV activity for
these three plant extracts. A statistically signiﬁcant decrease in
the number of infected cells was also observed for F2 plant
extract, (P = 0.0022), but with 29% of inhibition of HCV
infection, its anti-HCV activity is much less potent than F3,
F4, F5 extracts. The three other plant extracts, F1, F6, and F7,
displayed infection rates very similar to the control, indicat-
ing an absence of signiﬁcant inhibition of HCV infection.
These results indicate that F3 (T. dregeana root extract),
F4 (D. microcarpum stem bark extract), and F5 (P. capitata
leave extract) contain compounds that strongly inhibit HCV
infection.
Three Plant Extracts Inhibit HCV Entry in
Cell Culture
To further characterize anti-HCV activity of F3, F4, and F5,
each extract was added at diﬀerent steps of the infectious cycle,
either during the 2 h-inoculation step which represents the entry
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FIGURE 1 | Screening of plant extracts for anti-hepatitis C virus
(anti-HCV) activity. Huh-7 cells were inoculated with HCV cell culture system
(HCVcc) in the presence of plant extracts at 25 or 125 μg/mL for F3 and F5,
or 50 μM epigallocatechin gallate (EGCG), or 1 μM boceprevir for 2 h.
Dimethyl sulfoxide (DMSO) was used as a control. Cells were further
incubated in medium containing plant extracts or molecules for 28 h and cells
were fixed. (A) Nuclei were stained with 4′ ,6-diamidino-2-phenylindole (DAPI)
to quantify the number of cells. 37,235 cells were quantified in the control.
(B) Infectivity was measured by the use of immunofluorescence labeling of
HCV E1 envelope protein, and by calculating the number of infected cells
(33.3 ± 4.4% of infected cells in the DMSO control condition). Data are
expressed as a percentage of values measured with DMSO. Data are means
of values obtained in three independent experiments performed in triplicate.
Error bars represent SEM. Statistical analyses were performed using
Mann–Whithney non-parametric test. ∗∗P < 0.01.
step, or during the 28 h post-inoculation step which represents
the replication step, or during both steps, continuously. EGCG,
an inhibitor of the entry step, and boceprevir, an inhibitor
of the replication steps, were added as controls. The results
presented in Figure 2 clearly show a signiﬁcant decrease in
the number of HCV-infected cells when the extracts were
added during the inoculation step, as observed with EGCG.
Furthermore, no signiﬁcant antiviral eﬀect was observed when
the extracts were added during the replication step. Taken
together, these results suggest that F3, F4, and F5 extracts inhibit
HCV entry.
Effect on HCV Particle Release
Extracts that did not exhibit any anti-HCV activity in the ﬁrst
screening, aimed to identify entry or replication inhibitors,
could be active in another step of the virus infectious cycle,
the assembly/secretion step. To test this hypothesis, plant
extracts were added during 46 h post-inoculation, to allow
particle release in the medium. These particles were collected
and used to inoculate naive Huh-7 cells for 2 h. Cells were
then incubated with culture medium without extracts for
28 h, ﬁxed and subjected to immunoﬂuorescence labeling.
As shown in Figure 3, no signiﬁcant diﬀerence of HCV
infection was observed between the control and the diﬀer-
ent extracts tested showing that none aﬀect HCV particle
release. In contrast, when cells were treated post-inoculation
with 1 μM boceprevir, a strong inhibition of particle release was
observed, as expected, due to the blockade of the replication
step.
FIGURE 2 | Time-addition assay of plant extracts during HCV infection.
Huh7 cells were inoculated with HCVcc in the presence (“Entry” and
“Continuously”) or absence (“Replication”) of the plant extracts at 125 μg/mL
(F3 and F5) or 25 μg/mL (F4). Virus was removed and cells further incubated
with culture medium containing the plant extracts (“Replication” and
“Continuously”) or without plant extracts (“Entry”). EGCG at 50 μM and
boceprevir at 1 μM were added as controls during entry or replication,
respectively. Infectivity was measured by the use of immunofluorescence
labeling of HCV E1 envelope protein, and by calculating the number of
infected cells (24.1 ± 10.2% of infected cells in the DMSO control condition).
Data are expressed as a percentage of values measured with DMSO. Data are
means of values obtained in three independent experiments performed in
triplicate. Error bars represent SEM. Statistical analyses were performed using
Mann–Whithney non-parametric test. ∗P < 0.05, ∗∗∗P < 0.001.
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FIGURE 3 | Effect of plant extracts on HCV secretion. Huh7 cells were
inoculated with HCVcc for 2 h without compounds, virus was removed and
plant extracts or fractions were added during 46 h post-inoculation, to allow
particle release in the medium. These particles were collected and used to
inoculate naive Huh-7 cells for 2 h. Cells were then incubated with culture
medium without extracts for 28 h, fixed and subjected to immunofluorescence
labeling of E1 envelope protein to quantify infection level. Data are expressed
as a percentage of values measured with DMSO (46.7 ± 9.2% of infected
cells in the DMSO control condition). Data are means of values obtained in
three independent experiments performed in triplicate. Error bars represent
SEM.
Determination of the IC50 and the Cytotoxic
Effect of the Active Plant Extracts
The three plant extracts that were shown to strongly inhibit HCV
infection were further analyzed. Their IC50 were determined
by inoculating Huh-7 cells with HCVcc in the presence of
increasing concentrations of each extract (Figure 4). All the
extracts showed a clear dose-response inhibition of HCV
infection conﬁrming their antiviral activity. The IC50 values
calculated were found to be 16.16, 1.42, and 13.17 μg/mL
for F3, F4, and F5, respectively. Taken together these results
show that F3, F4, and F5 are inhibitors of HCV infection
and that F4 is ten times more active against HCV than
F3 and F5.
Finally, the cytotoxic eﬀect of F3, F4, and F5 extracts on
Huh-7 cells was determined by incubating the cells with increas-
ing concentrations of each plant extract for 24, 48, or 72 h.
Cellular viability was determined using a MTS test. The results
presented in Figure 5 show that when incubated with Huh-
7 cells for 72 h, F3, F4, and F5, are not toxic for the cells
up to 200, 100, and 800 μg/mL (the higher concentration
tested), respectively. However, for F3 or F4, the decrease in
the relative number of viable cells after 72 h of treatment
with 800 μg/mL of extract is not statistically signiﬁcant. The
median-lethal concentration (LC50) could not be determined
for F5 and was estimated to be 600 μg/mL for F3 and
300 μg/mL for F4. The therapeutic index, which is the LC50/IC50
ratio, was calculated for F3 and F4 to be approximately 37
and 211 respectively. This index could not be calculated for
FIGURE 4 | Dose-response study. Huh-7 cells were inoculated with HCVcc
in the presence of increasing concentration of plant extracts (A) F3, (B) F4,
and (C) F5, for 2 h. Inoculum was removed and cells were further incubated
with culture medium. Infectivity was measured by the use of
immunofluorescence labeling of HCV E1 envelope protein, and by calculating
the number of infected cells (14.7 ± 1.6%, 17.9 ± 1.4%, 15,6 ± 1.1% of
infected cells in the DMSO control condition for F3, F4, and F5 extracts
dose-response assay, respectively). Data are expressed as a percentage of
values obtained in the presence of DMSO. Data are means of values obtained
in 3 independent experiments performed in triplicate. Error bars represent
SEM.
F5, which was not toxic in Huh-7 cells, but is above 60
(800/13.17).
We estimated the IC95 (95% IC) and the IC99 (99% IC)
of each extract, allowing 1.5 log and 2 log inhibition of HCV
infection in Huh7 cells. For F3, IC95, and IC99 were estimated to
be 100 and 200 μg/mL respectively (Figure 4A), concentrations
that exhibited no eﬀect on cell viability even for 72 h exposure
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FIGURE 5 | Cellular toxicity of plant extracts. Huh-7 cells were cultured in
the presence of given concentrations of plant extracts (A) F3, (B) F4, and
(C) F5. The viability was monitored using an MTS-based viability assay after
24, 48, and 72 h. Data are expressed as a ratio to control, i.e., the condition
without extracts. Data are means of values obtained in three independent
experiments performed in triplicate. Error bars represent SEM.
(Figure 5A). For F4, IC95, and IC99 were estimated to be 15 and
25 μg/mL respectively (Figure 4B). These concentrations have
no impact on cell viability even for 72 h treatment (Figure 5B).
For F5, IC95, and IC99 were estimated to be 250 and 800 μg/mL,
respectively (Figure 4C). Even if these concentrations are quite
high, they have no impact on cell viability (Figure 5C).
In conclusion, F3, F4, and F5 are strong inhibitors of HCV
infection with IC50 between 1 and 16 μg/mL, LC50 higher than
300 μg/mL, and therapeutic index between 37 and 211. F4, with
an IC99 of 25 μg/mL and a therapeutic index of 211, is a very
interesting extract.
Discussion
In this paper, we examined the eﬀect of seven medicinal plants
extracts on HCV infection using the HCVcc system. These are
plants commonly used in Cameroonian traditional medicine
for the treatment of hepatic disorders. Three plants extracts
were found very active on this infectious model. These are
the methanol extracts from roots of T. dregeana (Meliaceae),
stem bark of D. microcarpum (Caesalpiniaceae) and leaves of
P. capitata (Loranthaceae). These extracts showed a strong inhibi-
tion of the viral infection at the diﬀerent tested concentrations.
They have distinguished themselves by their capacity to highly
interfere with the HCV life cycle and principally with the entry
step. Furthermore, these extracts are not toxic at the active
concentration, and display therapeutic indexes between 37 and
211. The four other plant extracts tested were inactive against
HCVcc. This could be explained by the diﬀerential phytochemi-
cal composition and the fact they don’t contain active ingredients
found in the F3, F4, and F5 extracts.
The three active extracts identiﬁed are HCV entry inhibitors.
These inhibitors could be used in combination with other
molecules or extracts that inhibit the replication step of
the virus like Sofosbuvir or Simeprevir. A multi-drug
therapy targeting the diﬀerent steps of the virus life cycle
might overcome the apparition of virus resistant mutants.
Furthermore, identiﬁcation of entry inhibitors is still needed
for treating patients undergoing liver transplantation in order
to reduce the risk of reinfection of the graft. This reinfec-
tion appears systematically after transplantation with adverse
outcomes.
Many studies previously reported the antiviral eﬀect of
medicinal plants against HCV infection and especially using
the HCVcc system. Recently, Wahyuni et al. (2013) investi-
gated the anti-HCV properties of 21 Indonesian medicinal plant
ethanol extracts. The authors showed that the presence of some
extracts during infection of Huh 7.5 cells with HCVcc genomes
of diﬀerent genotypes resulted in a dose-dependent inhibition of
infection. Five plants extracts were identiﬁed as the most active
ones and some of them like theMelanolepis multiglandulosa stem
extract and Ficus fistulosa leave extract mainly inhibited HCV
entry. Our results are similar to these ﬁndings but obtained with
diﬀerent plant species.
To best of our knowledge, there are no studies describing the
antiviral activities of the three activemedicinal plants identiﬁed in
our study, but information is available on their phyto-chemical
composition and related plants. A high polyphenolic content
(Lamien-Meda et al., 2008), bioactive diterpenes from fruits
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(Cavin et al., 2006) and carbohydrates from bark extract (Abreu
and Relva, 2002) have been highlighted in D. microcarpum.
Polyphenols in particular are known to be potent anti-HCV
agents, especially ﬂavonoïd compounds (Calland et al., 2012b).
Such compounds are not yet isolated in our plant extracts
and further experiments are needed to identify the active
compound inhibiting HCV entry present in D. microcarpum.
Previous studies on Loranthaceae showed many antiviral activi-
ties. An experimental research on the antiviral potential of
ethanol extracts from Loranthus yadoriki Sieb, a plant of the
Loranthaceae family, demonstrated an inhibitory eﬀect of two
components from these extracts on Coxsackie B3 virus (Wang
et al., 2000). A recent review on Loranthus parasiticus Merr,
another Loranthaceae, reported antiviral and antihepatotoxic
activities (Moghadamtousi et al., 2014). It was shown, in the
study, that the aqueous extract from aerial parts of this plant
elicited 59.8% and 27.8% inhibition of HIV-1 protease at doses
of 250 and 25 μg/mL, respectively and a signiﬁcant inhibition
of HIV-1-induced cytopathogenicity. Inhibitory activities were
also demonstrated on reverse transcriptase of avian myeloblas-
tosis virus with methanol and water extracts. A phytochemical
analysis of this plant led to the identiﬁcation of sesquiterpene
lactones such as coriamyrtin, tutin, corianin, and coriatin as the
most important group of secondary metabolites. In addition, two
known proanthocyanidins and (+)-catechin were identiﬁed from
the aqueous fraction of L. parasiticus leaves by comparing 1H
NMR and 13C NMR spectra with literature values (Wong et al.,
2012). P. capitata belongs to the same plant family, although
diﬀering by the genus. The eﬀects observed with Loranthus
species on HIV, Coxsackie and myeloblastosis viruses and here
on HCV, conﬁrm the antiviral potential of this plant.
Trichilia dregeana is a plant belonging to the Meliaceae
family. Plants from this family are commonly used in traditional
medicine for the treatment of malaria and inﬂammation. Anti-
HCV properties were also reported with some of them. Wahyuni
et al. (2013) showed that the ethanolic extract from Toona sureni
leaves signiﬁcantly inhibited the entry and post-entry steps of
diﬀerent HCV strains in cell culture. Wu et al. (2012) identi-
ﬁed 3-hydroxy caruilignan C from Swietenia macrophylla stems
as the most active ingredient of this plant against HCV. The
authors showed that this compound inhibited HCV replication
and induced IFN responsive genes. The eﬀects observed with
T. dregeana support these ﬁndings and demonstrate the potential
of Meliaceae against HCV infection. This result also suggests
the presence of ﬂavonolignans- type compounds in this plant
although no eﬀect was reported with these compounds on the
HCV entry. The antiviral properties of Meliaceae extracts were
also found with other viruses. The therapeutic eﬀect of meliacine,
an antiviral derived from Melia azedarach L., in mice genital
herpetic infection were shown for example by Petrera and Coto
(2009) and conﬁrmed by Tiwari et al. (2010) who reported the
same eﬀect in vitro with the neem (Azadirachta indica L.) bark
extract (NBE) against herpes simplex virus type-1 infection. In
that study, Tiwari et al. (2010) showed that NBE signiﬁcantly
blocked HSV-1 entry into cells at concentrations ranging from
50 to 100 μg/mL. Furthermore, authors also found that virions
treated with NBE failed to bind the cells, implicating its role as
an attachment step blocker. Likewise, cells treated with NBE also
inhibited HSV-1 glycoprotein mediated cell-to-cell fusion and
polykaryocytes formation, suggesting an additional role of NBE
at the viral fusion step.
These results prove the eﬃcacy of plant extracts in inhibit-
ing HCV infection. It would be interesting to identify the
active compounds present in these extracts, especially for
D. microcarpum stem extract that is very active at low concen-
tration (IC50 = 1.42 μg/mL, and IC99 = 25 μg/mL) and
encompasses a therapeutic index of 211. Experiments should be
performed to prove the activity of these extracts in pre-clinical
models such as primary human hepatocytes or humanized mice.
Then, clinical trials could be envisaged to ﬁrst, demonstrate
the innocuousness of the extracts in humans, and second their
eﬃcacy against HCV. The studied plants extracts or compounds
isolated from these extracts might not be used as unique anti-
HCV treatment but in combination with the therapeutic arsenal
to reduce the cost of the actual therapy and increase the number
of people with access to this therapy.
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